US8592373B2ActiveUtilityA1

Methods for prevention and treatment of acute renal injury

93
Assignee: SZETO HAZEL HPriority: Feb 26, 2008Filed: Feb 22, 2012Granted: Nov 26, 2013
Est. expiryFeb 26, 2028(~1.6 yrs left)· nominal 20-yr term from priority
A61P 13/12A61P 13/02A61K 38/07C07K 5/1019C07K 5/1016A61K 38/06A61K 38/00
93
PatentIndex Score
20
Cited by
199
References
8
Claims

Abstract

The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method for treating contrast-induced nephropathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a peptide selected from the group-consisting of Phe-D-Arg-Phe-Lys-NH 2  (SS-20) and D-Arg-2′6′Dmt-Lys-Phe-NH 2  (SS-31). 
     
     
       2. The method of  claim 1 , wherein the contrast-induced nephropathy comprises an inflammatory response. 
     
     
       3. The method of  claim 1 , wherein the contrast-induced nephropathy comprises a decrease in glomerular filtration rate (GFR) compared to a healthy control subject. 
     
     
       4. The method of  claim 1 , wherein the contrast-induced nephropathy comprises a decrease in urinary output compared to a healthy control subject. 
     
     
       5. The method of  claim 1 , wherein the contrast-induced nephropathy comprises an increase in renal tubular apoptosis compared to a healthy control subject. 
     
     
       6. The method of  claim 1 , wherein the contrast-induced nephropathy comprises loss of renal tubular brush border and/or renal vacuolization. 
     
     
       7. The method of  claim 1 , wherein the contrast-induced nephropathy comprises increased serum Cystatin C levels and/or serum creatinine levels compared to a healthy control subject. 
     
     
       8. The method of  claim 1 , wherein the contrast-induced nephropathy comprises proteinuria and/or increased urinary creatinine compared to a healthy control subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.